ITGA9 and neoplasm: The use of CRISPR/Cas9 for the knockout of ITGA9, resulted in reduced cancer stem cell (CSC)-like properties, tumor angiogenesis, tumor growth, and metastasis by promoting β-catenin degradation in TNBC (Wang Z. et al., 2019).